Patient Satisfaction With the Management of a Stopped Pregnancy in the First Trimester (MYFEFACY)

Toulouse University Hospital

Status: Completed

Conditions: Pregnancy Loss, Early

Treatments: Procedure: Endo-uterine aspiration; Drug: Medical treatment with Mifégyne® and MisoOne®

Study type: Interventional

Funder types: Other

Identifiers

NCT05049980

RC31/21/0328

Details and patient eligibility

About

The clinical practice recommendations highlight the fact that the patient's choice concerning the management of her aborted pregnancy in the first trimester should be privileged, after clear and appropriate information on the available treatments, in order to improve his experience and reduce the negative psychological symptoms that can generate an alteration in the quality of life, in the aftermath of the loss of pregnancy.

The present study will describe the efficacy, satisfaction and tolerance of patients benefiting from medical treatment with Mifégyne® and MisoOne® versus those benefiting from surgical treatment by endo-uterine aspiration for the management of a pregnancy stopped during the first trimester at the Toulouse University Hospital

Enrollment: 52 patients

Sex: Female

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any adult patient presenting to the gynecological emergency department of the Paule de Viguier Hospital in Toulouse for whom a diagnosis of an arrested pregnancy in the first trimester is made
• Whose cranio-caudal length of the embryo measured by ultrasound is less than 25 mm or having a clear egg
• Having agreed to the study (written or verbal) after clear and fair information
• Who understands and reads French

Exclusion criteria

• Medical contraindication to treatment with Mifégyne® or MisoOne®
• Hemodynamically unstable patient requiring urgent surgical treatment.
• Protected adult patient (guardianship, curatorship, safeguard of justice)

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

52 participants in 2 patient groups

Medical treatment

Experimental group

Description:

Patients choosing medical treatment with Mifégyne® and MisoOne®

Treatment:

Drug: Medical treatment with Mifégyne® and MisoOne®

Surgical treatment

Active Comparator group

Description:

Patients choosing surgical treatment by endo-uterine aspiration.

Treatment:

Procedure: Endo-uterine aspiration